Drugs / GTB-360
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06594445 | Nov 2024 → Mar 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GTB-360 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06594445 ↗ |
| Modality | Other / unclassified | “Tri-Specific Killer Engager (TriKE®)” NCT06594445 ↗ |
| Route | Other | “administered by a continuous infusion (CI)” NCT06594445 ↗ |